

Authorisation No. 511351-102608771

## DECISION

### Operating Authorisation for Medicinal Products

#### Subject

1. Application date: 25.03.2019, Number 102608771
2. Applicant: Rivopharm SA
3. Reason for application:
  - Renewal
  - Change of Qualified Person
4. Number of authorisation valid until now: 504552
5. Legal bases:
  - Federal Act on Therapeutic Products (LATer; RS 812.21);
  - Ordinance on Authorisation of Medicinal Products (OAMed; RS 812.212.1)
  - Ordinance on Medicinal Products (OM; RS 812.212.21)
  - Ordinance on Fees of the Swiss Agency for Therapeutic Products (OEm-Swissmedic; RS 812.214.5)

#### Swissmedic decides as follows:

1. Holder of the Operating Authorisation  
**Rivopharm SA**  
Centro Insema  
6928 Manno
2. The number of this authorisation is 511351-102608771
3. The authorisation is granted for the following activities:
  - Manufacture of medicinal products
  - Import of medicinal products
  - Wholesale trade in medicinal products
  - Export of medicinal products
  - Foreign trade in medicinal products
4. Number of authorised operating sites: 1
5. The provisions contained in the annexes are applicable.
6. This authorisation of unlimited duration is valid starting from 02.12.2019.
7. Fee: CHF 10,800.00
8. This authorisation replaces the authorisation indicated as the subject hereof, starting from the validity date indicated at point 6.

swissmedic

Your reference: Daniele Casale  
Our reference: rya  
Case File Manager, direct phone: Alfred Ryf, +41 58 462 03 78  
Page 2/6

Authorisation No. 511351-102608771

Bern, 23.10.2019

Swissmedic, Swiss Agency for Therapeutic Products

(signature)

Claudia Gugler  
Centralised distribution

**Your contact:**

Inspectorates and Authorisations Division  
Secretariat telephone number: +41 58 462 04 55

**Appeal procedure:**

This decision may be the subject of an appeal, within a period of 30 days from its notification, to the Federal Administrative Court, Post Box, 9023 St-Gall, (art. 31 and 33 letter e of the Federal Act of 17 June 2005 on the Federal Administrative Court; RS 173.32). The statement of grounds of appeal shall include the conclusions, grounds and proof and bear the signature of the appellant or his/her representative; the decision appealed against and the documents invoked as evidence shall be attached thereto (art. 52 of the Federal Act of 20 December 1968 on Administrative Procedure; RS 172.021).

Copy for information to:

- the Chief Pharmacist for the Canton of Ticino
- the Regional Inspection Service for Southern Switzerland (IRM-S)

Authorisation No. 511351-102608771

## Annex 1

### Authorised operating site 1000456

Rivopharm SA  
Centro Insema  
6928 Manno

### Qualified Person(s)

QP 1  
Casale, Daniele  
Dr. Master's Degree in Pharmaceutical Biotechnology

Authorisation No. 511351-102608771

**Authorised activities / Conditions / Reservations**

No.	Description	Scope*	QP
<b>1</b>	<b>MANUFACTURE OF MEDICINAL PRODUCTS (EXCLUDING LABILE BLOOD PRODUCTS)</b>		
<b>1.2</b>	<b>Non-sterile products</b>		
1.2.1	Non-sterile products (manufacturing activities for the following pharmaceutical forms)		
1.2.1.1	Hard capsules	H/V, I	1
1.2.1.13	Tablets	H/V, I	1
1.2.2	Certification of batches (technical release)	H/V, I	1
<b>1.5</b>	<b>Packaging</b>		
1.5.1	Primary packaging	H/V, I	1
1.5.1.1	Hard capsules	H/V, I	1
1.5.1.13	Tablets	H/V	1
1.5.2	Secondary packaging		
<b>1.6</b>	<b>Quality control</b>		
1.6.2	Microbiological analyses without sterility test	H/V, I	1
1.6.3	Chemical / physical analyses	H/V, I	1
<b>S.2</b>	<b>IMPORT OF MEDICINAL PRODUCTS (EXCLUDING LABILE BLOOD PRODUCTS)</b>		
<b>S.2.2</b>	<b>Import of ready-to-use medicinal products, including release to market</b>		
S.2.2.1	Medicinal products (excluding immunological and blood products)	-	1
<b>S.2.3</b>	<b>Import of ready-to-use medicinal products, excluding release to market</b>		
S.2.3.1	Medicinal products (excluding immunological and blood products)	-	1
S.2.3.4	Import of ready-to-use medicinal products, excluding release to market is limited to:		
S.2.3.4.1	Import of products intended for re-export	-	1
S.2.3.4.2	Import of products under a mandate granted by the product approval holder	-	1
<b>S.4</b>	<b>WHOLESALE TRADE IN MEDICINAL PRODUCTS (EXCLUDING LABILE BLOOD PRODUCTS)</b>		
<b>S.4.1</b>	<b>Wholesale trade in non-ready-to-use medicinal products</b>		
S.4.1.1	Medicinal products (excluding immunological and blood products)	-	1
<b>S.4.2</b>	<b>Wholesale trade in ready-to-use medicinal products, including release to market</b>		
S.4.2.1	Medicinal products (excluding immunological and blood products)	-	1
<b>S.5</b>	<b>EXPORT OF MEDICINAL PRODUCTS (EXCLUDING LABILE BLOOD PRODUCTS)</b>		
<b>S.5.2</b>	<b>Export of ready-to-use medicinal products</b>		
S.5.2.1	Medicinal products (excluding immunological and blood products)	-	1

Authorisation No. 511351-102608771

<b>No.</b>	<b>Description</b>	<b>Scope*</b>	<b>QP</b>
<b>S.6</b>	<b>FOREIGN TRADE IN MEDICINAL PRODUCTS (EXCLUDING LABILE BLOOD PRODUCTS)</b>		
<b>S.6.1</b>	<b>Foreign trade in non-ready-to-use medicinal products, without storage in Switzerland</b>		
S.6.1.1	Medicinal products (excluding immunological and blood products)	-	1
<b>S.6.2</b>	<b>Foreign trade in ready-to-use medicinal products, without storage in Switzerland</b>		
S.6.2.1	Medicinal products (excluding immunological and blood products)	-	1

\* see last page

[QR code]

Authorisation No. 511351-102608771

**Scope of validity of authorised activities (legend valid for all annexes)**

- H/V Medicinal products for human medicine (medicinal products for human use) and veterinary medicine (medicinal products for veterinary use). Medicinal products for clinical studies are not included.
- V Exclusively, medicinal products for veterinary medicine (medicinal products for veterinary use).
- I Medicinal products for human medicine (medicinal products for human use) for clinical studies.
- Scope not specified/delimited.

